-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
*Only for medical professionals to read and refer to "2021 Alzheimer's Disease Prevention and Treatment Hot Issues Seminar and Diagnosis and Treatment Elite Forum" was held on September 15, 2021, and was a complete success, with more than 110,000 online viewers
.
The conference was sponsored by the Department of Neurology, Xuanwu Hospital of Capital Medical University, and the National Geriatrics Clinical Research Center, co-organized by China AD Preclinical Alliance, Beijing Cognitive Neuroscience Society, and undertaken by Beijing Chaonei Technology Development Co.
, Ltd.
, aiming to promote the Alzheimer’s The exchange of the latest achievements in the field of mirabilis research promotes the popularization of Alzheimer’s disease
.
It is understood that during the seminar, the "Alzheimer's disease pre-clinical Chinese awareness and consultation rate survey white paper 2021" was also announced to the public for the first time
.
This conference invited more than 10 domestic heavyweight experts to report on the hot issues and research results of Alzheimer's disease prevention and treatment online
.
In addition, it will also focus on discussing how both doctors and patients work together to fight the disease
.
September 21 is "World Alzheimer's Day", and the meeting is held on this occasion, which has even more positive significance
.
According to insiders, in order to strengthen the importance of medical workers in the field of neurology on the early diagnosis and early intervention of Alzheimer’s disease, this conference released the "Alzheimer’s disease pre-clinical awareness rate and consultation rate among Chinese people" for the first time to the society.
Investigation White Paper 2021
.
The content was extensively investigated by the China AD Preclinical Alliance led by Professor Han Ying.
After in-depth summary, it has revealed the public's awareness of Alzheimer's disease in China and the existing problems
.
The contents of this white paper on the survey of patients with Alzheimer's disease in China mainly focus on the awareness of Alzheimer's disease (AD) and the degree of attention paid to them by residents of various provinces and cities in China
.
The questionnaire designed this time focuses on three questions of the subjects: "Do you know what Alzheimer's disease is?", "Do you know that subjective cognitive decline in Alzheimer's disease in the preclinical stage?" and "Is it because of self-conscious memory loss?" , Can’t concentrate and have taken the initiative to go to the hospital for treatment?”
.
In addition, the questionnaire also covers the following content: the subjects’ age, gender, education level, province, occupation, disposable income status, marital status, relationship between family members and other basic information
.
According to Professor Han Ying’s team members, the scope of this survey involves 34 provinces, municipalities, and autonomous regions across the country, and is mainly led by Professor Han Ying from Xuanwu Hospital.
Specific implementation by member units
.
At present, more than 180 memory clinics in public hospitals in China have joined the China AD Preclinical Alliance, and the relevant person in charge of each alliance unit is also the backbone of scientific research in the field of cognitive impairment in this hospital
.
The expert teams of various alliance units widely publicized and actively distributed the questionnaire, and played a leading role in this nationwide survey
.
Secondly, the survey also used the Baidu platform and Chaonei.
com's official website platform to give full play to the advantages of the Internet, further expand the scope of the subject population, and make the collected samples more representative
.
In addition, the conference has two highlights: 1 Comprehensively review the methods of early diagnosis and early treatment of Alzheimer’s disease.
Well-known domestic experts in the field of Alzheimer’s disease In-depth interpretation of diagnosis, differential diagnosis, intervention measures and other aspects, combined with typical cases to comprehensively comb the key methods of early diagnosis and early treatment of Alzheimer's disease
.
According to Professor Han Ying, the current routine AD diagnosis methods include clinical examination, neuropsychological scale examination, blood test, and brain MRI.
After the doctor comprehensively analyzes the examination results, it is recommended to further check amyloid-PET to confirm the diagnosis as soon as possible.
, Or follow up once a year to dynamically observe the trend of changes in the condition
.
In fact, more simple and efficient diagnostic methods have been continuously proposed by the team, such as plasma Aβ detection and urine AD7cNTP examination, which can help early detection of Alzheimer's disease
.
However, the reliability and validity have yet to be further verified by multi-center and large samples
.
In 2020, Professor Han Ying and Professor Frank Jessen of the University of Cologne, Germany, successfully applied for the support of the National Natural Science Foundation of China's key international cooperation projects: "Comparative study of subjective cognitive decline between China and Germany based on imaging genomics and AD early diagnosis system Construction", Professor Frank Jessen unified the concept of subjective cognitive decline in the preclinical stage of AD for the first time in the world
.
The two sides have joined forces, and the results of the early diagnosis of AD are worth looking forward to
.
2 Doctors and patients work together to build a defense line for disease prevention and control Whether the efforts of medical institutions and medical workers in the prevention and treatment of Alzheimer’s disease can illuminate the road to early diagnosis and treatment of Alzheimer’s disease depends on the public’s recognition of the disease.
Knowing the degree, the prevention and treatment of Alzheimer's disease requires the participation of all people
.
"In fact, in terms of hardware, domestic clinical research is almost the same as that of advanced foreign countries, such as the United States, Germany, and the Netherlands, and we are even stronger in some aspects
.
"Professor Han said, "As far as I know, many hospitals in our country can carry out amyloid-PET examinations, and the amount exceeds the amount used abroad
.
"
"" In terms of drug treatment, both domestic and foreign countries have their own merits.
The FDA has just approved a monoclonal antibody targeted amyloid for the treatment of Alzheimer's disease.
The mannite sodium used to treat Alzheimer's disease provides a reliable drug weapon for the realization of the treatment of Alzheimer's disease in the preclinical stage
.
In addition to drug treatments for Alzheimer’s disease, there are non-drug interventions, especially in the pre-clinical stage.
National treasures such as Tai Chi in our country are also good non-drug interventions.
We can learn from each other, learn from each other, and cooperate together.
Win
.
However, there is a fact that makes Professor Han feel a long way to go, that is, the level of support for clinical trials by ordinary people, especially once participating in a certain clinical trial, the follow-up adherence rate is generally not good enough in our country
.
She hopes that, whether it is at the national level, hospital level or expert level, it will be able to better promote Alzheimer's disease popularization and raise the nation's awareness of the disease
.
Only by truly understanding AD and understanding its later stage of harm, can we pay attention to the early diagnosis and early treatment of AD, and improve the compliance of patients with treatment
.
Regarding the specific content of this conference, the follow-up "Medical Neurology Channel" will publish a series of articles, so stay tuned! Contribution/Reprint/Business Cooperation: yxjsjbx@yxj.
org.
cn
.
The conference was sponsored by the Department of Neurology, Xuanwu Hospital of Capital Medical University, and the National Geriatrics Clinical Research Center, co-organized by China AD Preclinical Alliance, Beijing Cognitive Neuroscience Society, and undertaken by Beijing Chaonei Technology Development Co.
, Ltd.
, aiming to promote the Alzheimer’s The exchange of the latest achievements in the field of mirabilis research promotes the popularization of Alzheimer’s disease
.
It is understood that during the seminar, the "Alzheimer's disease pre-clinical Chinese awareness and consultation rate survey white paper 2021" was also announced to the public for the first time
.
This conference invited more than 10 domestic heavyweight experts to report on the hot issues and research results of Alzheimer's disease prevention and treatment online
.
In addition, it will also focus on discussing how both doctors and patients work together to fight the disease
.
September 21 is "World Alzheimer's Day", and the meeting is held on this occasion, which has even more positive significance
.
According to insiders, in order to strengthen the importance of medical workers in the field of neurology on the early diagnosis and early intervention of Alzheimer’s disease, this conference released the "Alzheimer’s disease pre-clinical awareness rate and consultation rate among Chinese people" for the first time to the society.
Investigation White Paper 2021
.
The content was extensively investigated by the China AD Preclinical Alliance led by Professor Han Ying.
After in-depth summary, it has revealed the public's awareness of Alzheimer's disease in China and the existing problems
.
The contents of this white paper on the survey of patients with Alzheimer's disease in China mainly focus on the awareness of Alzheimer's disease (AD) and the degree of attention paid to them by residents of various provinces and cities in China
.
The questionnaire designed this time focuses on three questions of the subjects: "Do you know what Alzheimer's disease is?", "Do you know that subjective cognitive decline in Alzheimer's disease in the preclinical stage?" and "Is it because of self-conscious memory loss?" , Can’t concentrate and have taken the initiative to go to the hospital for treatment?”
.
In addition, the questionnaire also covers the following content: the subjects’ age, gender, education level, province, occupation, disposable income status, marital status, relationship between family members and other basic information
.
According to Professor Han Ying’s team members, the scope of this survey involves 34 provinces, municipalities, and autonomous regions across the country, and is mainly led by Professor Han Ying from Xuanwu Hospital.
Specific implementation by member units
.
At present, more than 180 memory clinics in public hospitals in China have joined the China AD Preclinical Alliance, and the relevant person in charge of each alliance unit is also the backbone of scientific research in the field of cognitive impairment in this hospital
.
The expert teams of various alliance units widely publicized and actively distributed the questionnaire, and played a leading role in this nationwide survey
.
Secondly, the survey also used the Baidu platform and Chaonei.
com's official website platform to give full play to the advantages of the Internet, further expand the scope of the subject population, and make the collected samples more representative
.
In addition, the conference has two highlights: 1 Comprehensively review the methods of early diagnosis and early treatment of Alzheimer’s disease.
Well-known domestic experts in the field of Alzheimer’s disease In-depth interpretation of diagnosis, differential diagnosis, intervention measures and other aspects, combined with typical cases to comprehensively comb the key methods of early diagnosis and early treatment of Alzheimer's disease
.
According to Professor Han Ying, the current routine AD diagnosis methods include clinical examination, neuropsychological scale examination, blood test, and brain MRI.
After the doctor comprehensively analyzes the examination results, it is recommended to further check amyloid-PET to confirm the diagnosis as soon as possible.
, Or follow up once a year to dynamically observe the trend of changes in the condition
.
In fact, more simple and efficient diagnostic methods have been continuously proposed by the team, such as plasma Aβ detection and urine AD7cNTP examination, which can help early detection of Alzheimer's disease
.
However, the reliability and validity have yet to be further verified by multi-center and large samples
.
In 2020, Professor Han Ying and Professor Frank Jessen of the University of Cologne, Germany, successfully applied for the support of the National Natural Science Foundation of China's key international cooperation projects: "Comparative study of subjective cognitive decline between China and Germany based on imaging genomics and AD early diagnosis system Construction", Professor Frank Jessen unified the concept of subjective cognitive decline in the preclinical stage of AD for the first time in the world
.
The two sides have joined forces, and the results of the early diagnosis of AD are worth looking forward to
.
2 Doctors and patients work together to build a defense line for disease prevention and control Whether the efforts of medical institutions and medical workers in the prevention and treatment of Alzheimer’s disease can illuminate the road to early diagnosis and treatment of Alzheimer’s disease depends on the public’s recognition of the disease.
Knowing the degree, the prevention and treatment of Alzheimer's disease requires the participation of all people
.
"In fact, in terms of hardware, domestic clinical research is almost the same as that of advanced foreign countries, such as the United States, Germany, and the Netherlands, and we are even stronger in some aspects
.
"Professor Han said, "As far as I know, many hospitals in our country can carry out amyloid-PET examinations, and the amount exceeds the amount used abroad
.
"
"" In terms of drug treatment, both domestic and foreign countries have their own merits.
The FDA has just approved a monoclonal antibody targeted amyloid for the treatment of Alzheimer's disease.
The mannite sodium used to treat Alzheimer's disease provides a reliable drug weapon for the realization of the treatment of Alzheimer's disease in the preclinical stage
.
In addition to drug treatments for Alzheimer’s disease, there are non-drug interventions, especially in the pre-clinical stage.
National treasures such as Tai Chi in our country are also good non-drug interventions.
We can learn from each other, learn from each other, and cooperate together.
Win
.
However, there is a fact that makes Professor Han feel a long way to go, that is, the level of support for clinical trials by ordinary people, especially once participating in a certain clinical trial, the follow-up adherence rate is generally not good enough in our country
.
She hopes that, whether it is at the national level, hospital level or expert level, it will be able to better promote Alzheimer's disease popularization and raise the nation's awareness of the disease
.
Only by truly understanding AD and understanding its later stage of harm, can we pay attention to the early diagnosis and early treatment of AD, and improve the compliance of patients with treatment
.
Regarding the specific content of this conference, the follow-up "Medical Neurology Channel" will publish a series of articles, so stay tuned! Contribution/Reprint/Business Cooperation: yxjsjbx@yxj.
org.
cn
